Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2009

Open Access 01-12-2009 | Research article

The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study

Authors: Gordon Goodall, Eric M Sarpong, Clarice Hayes, William J Valentine

Published in: BMC Endocrine Disorders | Issue 1/2009

Login to get access

Abstract

Background

Recent data have shown that type 2 diabetes patients in the UK delay initiating insulin on average for over 11 years after first being prescribed an oral medication. Using a published computer simulation model of diabetes we used UK-specific data to estimate the clinical consequences of immediately initiating insulin versus delaying initiation for periods in line with published estimates.

Methods

In the base case scenario simulated patients, with characteristics based on published UK data, were modelled as either initiating insulin immediately or delaying for 8 years. Clinical outcomes in terms of both life expectancy and quality-adjusted life expectancy and also diabetes-related complications (cumulative incidence and time to onset) were projected over a 35 year time horizon. Treatment effects associated with insulin use were taken from published studies and sensitivity analyses were performed around time to initiation of insulin, insulin efficacies and hypoglycaemia utilities.

Results

For patients immediately initiating insulin there were increases in (undiscounted) life expectancy of 0.61 years and quality-adjusted life expectancy of 0.34 quality-adjusted life years versus delaying initiation for 8 years. There were also substantial reductions in cumulative incidence and time to onset of all diabetes-related complications with immediate versus delayed insulin initiation. Sensitivity analyses showed that a reduced delay in insulin initiation or change in insulin efficacy still demonstrated clinical benefits for immediate versus delayed initiation.

Conclusion

UK type 2 diabetes patients are at increased risk of a large number of diabetes-related complications due to an unnecessary delay in insulin initiation. Despite clear guidelines recommending tight glycaemic control this failure to begin insulin therapy promptly is likely to result in needlessly reduced life expectancy and compromised quality of life.
Appendix
Available only for authorised users
Literature
1.
go back to reference Diabetes Atlas. 2003, Brussels: International Diabetes Federation, 2 Diabetes Atlas. 2003, Brussels: International Diabetes Federation, 2
2.
go back to reference American Diabetes Association: Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008, 31: 596-615. 10.2337/dc08-9017.CrossRef American Diabetes Association: Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008, 31: 596-615. 10.2337/dc08-9017.CrossRef
3.
go back to reference Jonsson B: Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002, 45: S5-12. 10.1007/s00125-002-0858-x.CrossRefPubMed Jonsson B: Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002, 45: S5-12. 10.1007/s00125-002-0858-x.CrossRefPubMed
4.
go back to reference Williams R, Van Gaal L, Lucioni C: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002, 45: S13-S17. 10.1007/s00125-001-0749-6.CrossRefPubMed Williams R, Van Gaal L, Lucioni C: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002, 45: S13-S17. 10.1007/s00125-001-0749-6.CrossRefPubMed
5.
go back to reference Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A: [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr. 2001, 126: 585-589. 10.1055/s-2001-14102.CrossRefPubMed Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A: [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr. 2001, 126: 585-589. 10.1055/s-2001-14102.CrossRefPubMed
7.
go back to reference Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995, 28: 103-117. 10.1016/0168-8227(95)01064-K.CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995, 28: 103-117. 10.1016/0168-8227(95)01064-K.CrossRefPubMed
8.
go back to reference The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329: 977-986. 10.1056/NEJM199309303291401.CrossRef The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329: 977-986. 10.1056/NEJM199309303291401.CrossRef
9.
go back to reference The UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.CrossRef The UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.CrossRef
10.
go back to reference The UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865. 10.1016/S0140-6736(98)07037-8.CrossRef The UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865. 10.1016/S0140-6736(98)07037-8.CrossRef
11.
go back to reference The Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000, 342: 381-389. 10.1056/NEJM200002103420603.CrossRef The Diabetes Control and Complications Trial-Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000, 342: 381-389. 10.1056/NEJM200002103420603.CrossRef
12.
go back to reference Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care. 1999, 22 (Suppl 2): B35-B39.PubMed Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care. 1999, 22 (Suppl 2): B35-B39.PubMed
13.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. 10.1136/bmj.321.7258.405.CrossRefPubMedPubMedCentral Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412. 10.1136/bmj.321.7258.405.CrossRefPubMedPubMedCentral
14.
go back to reference The ADVANCE Collaboration Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMoa0802987.CrossRef The ADVANCE Collaboration Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572. 10.1056/NEJMoa0802987.CrossRef
15.
go back to reference Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004, 141: 421-431.CrossRefPubMed Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004, 141: 421-431.CrossRefPubMed
16.
go back to reference American Diabetes Association: Standards of medical care in diabetes--2008. Diabetes Care. 2008, 31 (Suppl 1): S12-S54.CrossRef American Diabetes Association: Standards of medical care in diabetes--2008. Diabetes Care. 2008, 31 (Suppl 1): S12-S54.CrossRef
17.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559. 10.1056/NEJMoa0802743.CrossRefPubMed
18.
go back to reference Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32: 193-203. 10.2337/dc08-9025.CrossRefPubMedPubMedCentral Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32: 193-203. 10.2337/dc08-9025.CrossRefPubMedPubMedCentral
19.
go back to reference Marrero DG: Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone. 2007, 8: 33-40. 10.1016/S1098-3597(09)60006-5.CrossRefPubMed Marrero DG: Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. Clin Cornerstone. 2007, 8: 33-40. 10.1016/S1098-3597(09)60006-5.CrossRefPubMed
20.
go back to reference Calvert MJ, McManus RJ, Freemantle N: Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007, 57: 455-460.PubMedPubMedCentral Calvert MJ, McManus RJ, Freemantle N: Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007, 57: 455-460.PubMedPubMedCentral
21.
go back to reference Calvert MJ, McManus RJ, Freemantle N: The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract. 2007, 24: 224-229. 10.1093/fampra/cmm008.CrossRefPubMed Calvert MJ, McManus RJ, Freemantle N: The management of people with type 2 diabetes with hypoglycaemic agents in primary care: retrospective cohort study. Fam Pract. 2007, 24: 224-229. 10.1093/fampra/cmm008.CrossRefPubMed
22.
go back to reference Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement mecision-making. Curr Med Res Opin. 2004, 20: S5-S26. 10.1185/030079904X1980.CrossRefPubMed Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement mecision-making. Curr Med Res Opin. 2004, 20: S5-S26. 10.1185/030079904X1980.CrossRefPubMed
23.
go back to reference Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin. 2004, 20: S27-S40. 10.1185/030079904X2006.CrossRefPubMed Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin. 2004, 20: S27-S40. 10.1185/030079904X2006.CrossRefPubMed
24.
go back to reference Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002, 22: 340-349.CrossRefPubMed Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002, 22: 340-349.CrossRefPubMed
26.
go back to reference Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care. 2000, 38: 583-637. 10.1097/00005650-200006000-00004.CrossRefPubMed Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care. 2000, 38: 583-637. 10.1097/00005650-200006000-00004.CrossRefPubMed
27.
go back to reference National Institute for Clinical Excellence: Technology appraisal guidance - No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. London. 2002, 10.1056/NEJMoa075392. National Institute for Clinical Excellence: Technology appraisal guidance - No. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. London. 2002, 10.1056/NEJMoa075392.
28.
go back to reference Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007, 357: 1716-1730. 10.2337/dc06-1357.CrossRefPubMed Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007, 357: 1716-1730. 10.2337/dc06-1357.CrossRefPubMed
29.
go back to reference Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenpera S, Nijpels G, Vahatalo M: Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007, 30: 1364-1369. 10.1111/j.1464-5491.2007.02078.x.CrossRefPubMed Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenpera S, Nijpels G, Vahatalo M: Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007, 30: 1364-1369. 10.1111/j.1464-5491.2007.02078.x.CrossRefPubMed
30.
go back to reference Cook MN, Girman CJ, Stein PP, Alexander CM: Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007, 24: 350-358. 10.1111/j.1464-5491.2007.02279.x.CrossRefPubMed Cook MN, Girman CJ, Stein PP, Alexander CM: Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007, 24: 350-358. 10.1111/j.1464-5491.2007.02279.x.CrossRefPubMed
31.
go back to reference Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P: Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007, 24: 1412-1418. 10.1093/eurheartj/ehm518.CrossRefPubMed Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P: Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007, 24: 1412-1418. 10.1093/eurheartj/ehm518.CrossRefPubMed
32.
go back to reference Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L: Prognostic implications of hypoglycemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes. A report from the DIGAMI 2 trial. E Heart J. 2008, 29: 166-176. 10.1093/eurheartj/ehm518.CrossRef Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L: Prognostic implications of hypoglycemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes. A report from the DIGAMI 2 trial. E Heart J. 2008, 29: 166-176. 10.1093/eurheartj/ehm518.CrossRef
33.
go back to reference Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999, 99: 2626-2632. 10.2337/diacare.29.02.06.dc05-1558.CrossRefPubMed Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999, 99: 2626-2632. 10.2337/diacare.29.02.06.dc05-1558.CrossRefPubMed
34.
go back to reference Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006, 29: 254-258. 10.1007/s00125-009-1418-4.CrossRefPubMed Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006, 29: 254-258. 10.1007/s00125-009-1418-4.CrossRefPubMed
35.
go back to reference Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009, 52: 1732-1744. 10.1007/s00125-009-1441-5.CrossRefPubMedPubMedCentral Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009, 52: 1732-1744. 10.1007/s00125-009-1441-5.CrossRefPubMedPubMedCentral
36.
go back to reference Smith U, Gale EA: Does diabetes therapy influence the risk of cancer?. Diabetologia. 2009, 52: 1699-1708. 10.1001/jama.291.3.335.CrossRefPubMed Smith U, Gale EA: Does diabetes therapy influence the risk of cancer?. Diabetologia. 2009, 52: 1699-1708. 10.1001/jama.291.3.335.CrossRefPubMed
38.
go back to reference Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004, 291: 335-342. 10.1111/j.1600-0420.2007.00944.x.CrossRefPubMed Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004, 291: 335-342. 10.1111/j.1600-0420.2007.00944.x.CrossRefPubMed
39.
go back to reference Higgins GT, Khan J, Pearce IA: Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies?. Acta Ophthalmol Scand. 2007, 85: 772-776. 10.1093/fampra/cmm060.CrossRefPubMed Higgins GT, Khan J, Pearce IA: Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies?. Acta Ophthalmol Scand. 2007, 85: 772-776. 10.1093/fampra/cmm060.CrossRefPubMed
40.
go back to reference Bebb C, Coupland C, Stewart J, Kendrick D, Madeley R, Sturrock N, Burden R: Practice and patient characteristics related to blood pressure in patients with type 2 diabetes in primary care: a cross-sectional study. Fam Pract. 2007, 24: 547-554. 10.2337/diacare.28.11.2673.CrossRefPubMed Bebb C, Coupland C, Stewart J, Kendrick D, Madeley R, Sturrock N, Burden R: Practice and patient characteristics related to blood pressure in patients with type 2 diabetes in primary care: a cross-sectional study. Fam Pract. 2007, 24: 547-554. 10.2337/diacare.28.11.2673.CrossRefPubMed
41.
go back to reference Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005, 28: 2673-2679. 10.2337/diacare.28.11.2673.CrossRefPubMed Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005, 28: 2673-2679. 10.2337/diacare.28.11.2673.CrossRefPubMed
42.
go back to reference Phillips A: Starting patients on insulin therapy: diabetes nurse specialist views. Nurs Stand. 2007, 21: 35-40. Phillips A: Starting patients on insulin therapy: diabetes nurse specialist views. Nurs Stand. 2007, 21: 35-40.
Metadata
Title
The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study
Authors
Gordon Goodall
Eric M Sarpong
Clarice Hayes
William J Valentine
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2009
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-9-19

Other articles of this Issue 1/2009

BMC Endocrine Disorders 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.